244 related articles for article (PubMed ID: 28579554)
1. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
[TBL] [Abstract][Full Text] [Related]
2. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.
Niss O; Sholl A; Bleesing JJ; Hildeman DA
J Allergy Clin Immunol; 2015 Mar; 135(3):762-70. PubMed ID: 25174872
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
4. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
[TBL] [Abstract][Full Text] [Related]
6. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
7. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
Marega LF; Teocchi MA; Dos Santos Vilela MM
Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
11. Rare splicing defects of FAS underly severe recessive autoimmune lymphoproliferative syndrome.
Agrebi N; Ben-Mustapha I; Matoussi N; Dhouib N; Ben-Ali M; Mekki N; Ben-Ahmed M; Larguèche B; Ben Becher S; Béjaoui M; Barbouche MR
Clin Immunol; 2017 Oct; 183():17-23. PubMed ID: 28668589
[TBL] [Abstract][Full Text] [Related]
12. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS).
Lisco A; Wong CS; Price S; Ye P; Niemela J; Anderson M; Richards E; Manion M; Mystakelis H; Similuk M; Lo B; Stoddard J; Rosenzweig S; Vanpouille C; Rupert A; Maric I; Perez-Diez A; Parenti D; Burbelo PD; Rao VK; Sereti I
Front Immunol; 2019; 10():1193. PubMed ID: 31191551
[TBL] [Abstract][Full Text] [Related]
14. A rapid ex vivo clinical diagnostic assay for fas receptor-induced T lymphocyte apoptosis.
Lo B; Ramaswamy M; Davis J; Price S; Rao VK; Siegel RM; Lenardo MJ
J Clin Immunol; 2013 Feb; 33(2):479-88. PubMed ID: 23054345
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation.
Revel-Vilk S; Fischer U; Keller B; Nabhani S; Gámez-Díaz L; Rensing-Ehl A; Gombert M; Hönscheid A; Saleh H; Shaag A; Borkhardt A; Grimbacher B; Warnatz K; Elpeleg O; Stepensky P
Clin Immunol; 2015 Jul; 159(1):84-92. PubMed ID: 25931386
[TBL] [Abstract][Full Text] [Related]
16. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
[TBL] [Abstract][Full Text] [Related]
17. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
